Current status and perspectives in the treatment of Prader-Willi syndrome

Bibliography

• Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus, und Oligophrenie Nach Myatonieartigem Zustard in Neugeborenenalter. Schweiz Med Wschr 1956;86:1260
   Google Scholar
• Ledbetter DH, Riccardi VM, Airhart SD, et al. Deletions of chromosome 15 as a cause of the Prader-Willi syndrome. N Engl J Med 1981;304:325-9
   PubMed Web of Science ®Google Scholar
• Holm VA, Cassidy SB, Butler MG, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993;91:398-402
   PubMed Web of Science ®Google Scholar
• Gunay-Aygun M, Schwartz S, Heeger S, et al. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001;108:E92
   PubMed Web of Science ®Google Scholar
• Honea RA, Holsen LM, Lepping RJ, et al. The neuroanatomy of genetic subtype differences in Prader-Willi syndrome. Am J Med Genet B Neuropsychiatr Genet 2012;159B:243-53
   PubMed Web of Science ®Google Scholar
• Pascanu I, Ruff R, Banescu C, Skryptnyk C. Prader-Willi Syndrome with Associated Triple-X Mosaicism. Acta Endocrinol Bucharest 2010;6:521-31
   Web of Science ®Google Scholar
• Najera N, Gonzalez L, Perez DJ, et al. Small nuclear ribonucleoprotein polypeptide N quantitative methylation analysis in infants with central hypotonia. J Pediatr Endocrinol Metab 2011;24:595-8
   PubMed Web of Science ®Google Scholar
• Zeschnigk M, Schmitz B, Dittrich B, et al. Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. Hum Mol Genet 1997;6:387-95
   PubMed Web of Science ®Google Scholar
• Bush JR, Wevrick R. Loss of the Prader-Willi obesity syndrome protein necdin promotes adipogenesis. Gene 2012;497:45-51
   PubMed Web of Science ®Google Scholar
• Hogart A, Nagarajan RP, Patzel KA, et al. 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum Mol Genet 2007;16:691-703
   PubMed Web of Science ®Google Scholar
• Zhang Z, Falaleeva M, Agranat-Tamir L, et al. The 5' untranslated region of the serotonin receptor 2C pre-mRNA generates miRNAs and is expressed in non-neuronal cells. Exp Brain Res 2013;230:387-94
   PubMed Web of Science ®Google Scholar
• Kuwajima T, Nishimura I, Yoshikawa K. Necdin promotes GABAergic neuron differentiation in cooperation with Dlx homeodomain proteins. J Neurosci 2006;26:5383-92
   PubMed Web of Science ®Google Scholar
• Lucignani G, Panzacchi A, Bosio L, et al. GABA A receptor abnormalities in Prader-Willi syndrome assessed with positron emission tomography and [11C]flumazenil. Neuroimage 2004;22:22-8
   PubMed Web of Science ®Google Scholar
• Badiu C. Endocrine Management in Prader-Willi Syndrome. Acta Endocrinol Bucharest 2012;8:99-105
   Web of Science ®Google Scholar
• Theodoridis CG, Brown GA, Chance GW, Rudd BT. Plasma growth hormone levels in children with the Prader-Willi syndrome. Aust Paediatr J 1971;7:24-7
   PubMedGoogle Scholar
• Wit JM, Van den Brande JL. Plasma somatomedin activity and urinary hydroxyproline excretion during administration of human growth hormone in children with short stature. Short-term effects. Horm Res 1984;19:205-15
   PubMedGoogle Scholar
• Lee PD, Wilson DM, Rountree L, et al. Linear growth response to exogenous growth hormone in Prader-Willi syndrome. Am J Med Genet 1987;28:865-71
   PubMed Web of Science ®Google Scholar
• Goldstone AP, Unmehopa UA, Swaab DF. Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity. Clin Endocrinol (Oxf) 2003;58:743-55
   PubMed Web of Science ®Google Scholar
• Feigerlova E, Diene G, Conte-Auriol F, et al. Hyperghrelinemia precedes obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:2800-5
   PubMed Web of Science ®Google Scholar
• Deal CL, Tony M, Hoybye C, et al. GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-87
   PubMed Web of Science ®Google Scholar
• Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-iv
   PubMed Web of Science ®Google Scholar
• Diene G, Mimoun E, Feigerlova E, et al. Endocrine disorders in children with Prader-Willi syndrome–data from 142 children of the French database. Horm Res Paediatr 2010;74:121-8
   PubMed Web of Science ®Google Scholar
• Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97
   PubMed Web of Science ®Google Scholar
• Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2008;68:919-25
   PubMed Web of Science ®Google Scholar
• Reus L, Pelzer BJ, Otten BJ, et al. Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial. Res Dev Disabil 2013;34:3092-103
   PubMed Web of Science ®Google Scholar
• Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 2007;31:1567-70
   PubMed Web of Science ®Google Scholar
• Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006;311:230-2
   PubMed Web of Science ®Google Scholar
• Morabito MV, Abbas AI, Hood JL, et al. Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome. Neurobiol Dis 2010;39:169-80
   PubMed Web of Science ®Google Scholar
• Kim GW, Lin JE, Blomain ES, Waldman SA. Anti-Obesity Pharmacotherapy: new Drugs and Emerging Targets. Clin Pharmacol Ther 2013; published online, doi:clpt2013204 [pii];10.1038/clpt.2013.204
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-77
   PubMed Web of Science ®Google Scholar
• Wang GJ, Tomasi D, Volkow ND, et al. Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. Int J Obes (Lond) 2013; published online, doi:ijo2013145 [pii];10.1038/ijo.2013.145
   Web of Science ®Google Scholar
• Mercer RE, Michaelson SD, Chee MJ, et al. Magel2 is required for leptin-mediated depolarization of POMC neurons in the hypothalamic arcuate nucleus in mice. PLoS Genet 2013;9:e1003207
   PubMed Web of Science ®Google Scholar
• Bittel DC, Kibiryeva N, Sell SM, et al. Whole genome microarray analysis of gene expression in Prader-Willi syndrome. Am J Med Genet A 2007;143:430-42
   Google Scholar
• Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:870-3
   PubMed Web of Science ®Google Scholar
• Zlotkin SH, Fettes IM, Stallings VA. The effects of naltrexone, an oral beta-endorphin antagonist, in children with the Prader-Willi syndrome. J Clin Endocrinol Metab 1986;63:1229-32
   PubMed Web of Science ®Google Scholar
• Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013;15:863-6
   PubMed Web of Science ®Google Scholar
• Howland RH. Therapies for obesity and medication-associated weight gain. J Psychosoc Nurs Ment Health Serv 2013;51:13-16
   Web of Science ®Google Scholar
• Shapira NA, Lessig MC, He AG, et al. Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRI. J Neurol Neurosurg Psychiatry 2005;76:260-2
   PubMed Web of Science ®Google Scholar
• Shapira NA, Lessig MC, Lewis MH, et al. Effects of topiramate in adults with Prader-Willi syndrome. Am J Ment Retard 2004;109:301-9
   PubMedGoogle Scholar
• Gadde KM, Kopping MF, Wagner HR, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012;172:1557-64
   PubMedGoogle Scholar
• Hochberg I, Hochberg Z. Expanding the definition of hypothalamic obesity. Obes Rev 2010;11:709-21
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52
   PubMed Web of Science ®Google Scholar
• Butler MG. Management of obesity in Prader-Willi syndrome. Nat Clin Pract Endocrinol Metab 2006;2:592-3
   PubMedGoogle Scholar
• Motaghedi R, Lipman EG, Hogg JE, et al. Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. Eur J Med Genet 2011;54:14-18
   PubMed Web of Science ®Google Scholar
• Tan TM, Vanderpump M, Khoo B, et al. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2004;89:4162-5
   PubMed Web of Science ®Google Scholar
• Tzotzas T, Papazisis K, Perros P, Krassas GE. Use of somatostatin analogues in obesity. Drugs 2008;68:1963-73
   PubMed Web of Science ®Google Scholar
• De Waele K, Ishkanian SL, Bogarin R, et al. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur J Endocrinol 2008;159:381-8
   PubMed Web of Science ®Google Scholar
• Seetho IW, Jones G, Thomson GA, Fernando DJ. Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res Clin Pract 2011;92:e1-2
   PubMed Web of Science ®Google Scholar
• Sze L, Purtell L, Jenkins A, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011;96:E1314-19
   PubMed Web of Science ®Google Scholar
• Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2011;13:169-80
   PubMed Web of Science ®Google Scholar
• Lee HJ, Choe YH, Lee JH, et al. Delayed response of amylin levels after an oral glucose challenge in children with Prader-Willi syndrome. Yonsei Med J 2011;52:257-62
   PubMed Web of Science ®Google Scholar
• Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92:1754-7
   PubMed Web of Science ®Google Scholar
• Allas S, Abribat T. Clinical perspectives for ghrelin-derived therapeutic products. Endocr Dev 2013;25:157-66
   PubMedGoogle Scholar
• Uzuki Y, Uetake K, Toshihiro T. Liraglutide treatment in A patient with diabetes mellitus in Prader-Willi syndrome. Acta Endocrinol Bucharest 2012;8:107-11
   Google Scholar
• Cyganek K, Koblik T, Kozek E, et al. Liraglutide therapy in Prader-Willi syndrome. Diabet Med 2011;28:755-6
   PubMed Web of Science ®Google Scholar
• Scheimann AO, Butler MG, Gourash L, et al. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2008;46:80-3
   PubMed Web of Science ®Google Scholar
• De Peppo F, Di Giorgio G, Germani M, et al. BioEnterics intragastric balloon for treatment of morbid obesity in Prader-Willi syndrome: specific risks and benefits. Obes Surg 2008;18:1443-9
   PubMed Web of Science ®Google Scholar
• Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg 2005;15:1161-4
   PubMed Web of Science ®Google Scholar
• Stevenson DA, Heinemann J, Angulo M, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2007;45:272-4
   PubMed Web of Science ®Google Scholar
• de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:1649-54
   PubMed Web of Science ®Google Scholar
• Corrias A, Grugni G, Crino A, et al. Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2011; published online, doi:10.1111/j.1365-2265.2011.04313.x
   Web of Science ®Google Scholar
• Grugni G, Beccaria L, Corrias A, et al. Central adrenal insufficiency in young adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2013;79:371-8
   PubMed Web of Science ®Google Scholar
• Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, et al. Testicular failure in boys with Prader-Willi syndrome: longitudinal studies of reproductive hormones. J Clin Endocrinol Metab 2012;97:E452-9
   PubMed Web of Science ®Google Scholar
• Radicioni AF, Di GG, Grugni G, et al. Multiple forms of hypogonadism of central, peripheral or combined origin in males with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2012;76:72-7
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Hirsch HJ, Pollak Y, et al. Management of hypogonadism in adolescent girls and adult women with Prader-Willi syndrome. Am J Med Genet A 2013;161:3030-4
   Web of Science ®Google Scholar
• Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012;14:10-26
   PubMed Web of Science ®Google Scholar
• Eiholzer U, Grieser J, Schlumpf M, l'Allemand D. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res 2007;68:178-84
   PubMedGoogle Scholar
• Vogels A, Moerman P, Frijns JP, Bogaert GA. Testicular histology in boys with Prader-Willi syndrome: fertile or infertile? J Urol 2008;180:1800-4
   PubMed Web of Science ®Google Scholar
• Kido Y, Sakazume S, Abe Y, et al. Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader-Willi syndrome: an observational study. Am J Med Genet A 2013;161:2167-73
   Web of Science ®Google Scholar
• Vaiani E, Herzovich V, Chaler E, et al. Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2 years of life. Clin Endocrinol (Oxf) 2010;73:546-50
   PubMed Web of Science ®Google Scholar
• Butler MG, Theodoro M, Skouse JD. Thyroid function studies in Prader-Willi syndrome. Am J Med Genet A 2007;143:488-92
   Google Scholar
• Nakamura Y, Nagai T, Iida T, et al. Epidemiological aspects of scoliosis in a cohort of Japanese patients with Prader-Willi syndrome. Spine J 2009;9:809-16
   PubMed Web of Science ®Google Scholar
• Yang L, Zhan GD, Ding JJ, et al. Psychiatric illness and intellectual disability in the prader-willi syndrome with different molecular defects - a meta analysis. PLoS One 2013;8:e72640
   PubMed Web of Science ®Google Scholar
• Pignatti R, Mori I, Bertella L, et al. Exploring patterns of unwanted behaviours in adults with prader-willi syndrome. J Appl Res Intellect Disabil 2013;26:568-77
   PubMed Web of Science ®Google Scholar
• Araki S, Ohji T, Shiota N, et al. Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatr Int 2010;52:e1-3
   PubMed Web of Science ®Google Scholar
• Tauber M, Mantoulan C, Copet P, et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis 2011;6:47
   PubMed Web of Science ®Google Scholar
• Resnick JL, Nicholls RD, Wevrick R. Recommendations for the investigation of animal models of Prader-Willi syndrome. Mamm Genome 2013;24:165-78
   PubMed Web of Science ®Google Scholar